See more : EVE Energy Co., Ltd. (300014.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of ANGLE plc (ANPCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ANGLE plc, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Keywords Studios plc (KYYWY) Income Statement Analysis – Financial Results
- Maire Tecnimont S.p.A. (3OY1.F) Income Statement Analysis – Financial Results
- Paramount Global (PARAP) Income Statement Analysis – Financial Results
- Mid India Industries Limited (MIDINDIA.BO) Income Statement Analysis – Financial Results
- Investeringsforeningen Formuepleje – Better World (FPIBWEL.CO) Income Statement Analysis – Financial Results
ANGLE plc (ANPCF)
About ANGLE plc
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD multiplex analysis system for routine and focused multiplex analysis of DNA, RNA or protein biomarkers. The company was founded in 1994 and is based in Guildford, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.19M | 1.04M | 1.01M | 762.00K | 871.50K | 678.00K | 628.00K | 498.00K | 361.00K | 0.00 | 801.00K | 969.02K | 1.41M | 2.42M | 2.45M | 5.06M | 3.87M | 3.38M | 4.09M | 4.09M | 2.88M | 1.98M | 1.79M | 1.17M |
| Cost of Revenue | 2.59M | 428.00K | 302.00K | 165.00K | 1.55M | 155.00K | 169.00K | 123.00K | 107.00K | 3.78M | 0.00 | 1.56M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.90M | 2.67M | 3.02M | 2.57M |
| Gross Profit | -408.00K | 613.00K | 711.00K | 597.00K | -678.00K | 523.00K | 459.00K | 375.00K | 254.00K | -3.78M | 801.00K | -594.98K | 1.41M | 2.42M | 2.45M | 5.06M | 3.87M | 3.38M | 4.09M | 4.09M | -27.00K | -682.00K | -1.23M | -1.39M |
| Gross Profit Ratio | -18.66% | 58.89% | 70.19% | 78.35% | -77.80% | 77.14% | 73.09% | 75.30% | 70.36% | 0.00% | 100.00% | -61.40% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | -0.94% | -34.39% | -68.98% | -118.94% |
| Research & Development | 9.51M | 4.49M | 3.44M | 3.66M | 9.00M | 2.06M | 2.04M | 2.69M | 960.00K | 1.91M | 386.00K | 137.54K | 274.00K | 11.00K | 25.00K | 60.00K | 357.00K | 748.00K | 675.00K | 26.00K | 42.00K | 27.00K | 98.00K | 69.00K |
| General & Administrative | 382.00K | 557.00K | 342.00K | 372.00K | 139.50K | 236.00K | 400.00K | 125.00K | 60.00K | 0.00 | 188.00K | 158.36K | 216.56K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 3.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 382.00K | 557.00K | 342.00K | 372.00K | 3.47M | 236.00K | 400.00K | 125.00K | 60.00K | 3.78M | 188.00K | 158.36K | 216.56K | 0.00 | 0.00 | 0.00 | 0.00 | 15.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 11.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.35M | 0.00 | -640.00K | -2.50M | -3.91M | 2.04M | -2.38M | -2.38M | -46.00K | 0.00 | 294.00K | -106.00K |
| Operating Expenses | 21.35M | 24.82M | 17.95M | 14.33M | 12.47M | 11.42M | 9.39M | 7.81M | 5.70M | 3.88M | 3.49M | 2.56M | 118.00K | 2.85M | 4.30M | 5.94M | 18.80M | 6.23M | 14.03M | 14.03M | 2.90M | -6.00K | 185.00K | -277.00K |
| Cost & Expenses | 23.95M | 25.25M | 18.25M | 14.49M | 14.01M | 11.58M | 9.56M | 7.93M | 5.81M | 3.88M | 3.49M | 2.56M | 118.00K | 2.85M | 4.30M | 5.94M | 18.80M | 6.23M | 14.03M | 14.03M | 2.90M | 2.66M | 3.20M | 2.29M |
| Interest Income | 463.00K | 136.00K | 29.00K | 78.00K | 60.00K | 28.00K | 8.00K | 25.00K | 22.00K | 9.00K | 112.00K | 41.54K | 12.00K | 1.00K | 0.00 | 14.00K | 50.00K | 202.00K | 132.00K | 132.00K | 46.00K | 11.00K | 16.00K | 8.00K |
| Interest Expense | 325.00K | 368.00K | 157.00K | 92.00K | 99.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 8.00K | 8.00K | 1.00K | 18.00K | 5.00K | 2.00K | 3.00K | 8.00K | 5.00K | 4.00K | 5.00K |
| Depreciation & Amortization | 2.31M | 2.01M | 1.47M | 1.36M | 1.34M | 1.07M | 787.00K | 423.00K | 385.00K | 315.00K | 156.00K | 326.96K | 39.00K | 94.00K | 63.00K | 56.00K | 142.00K | 68.00K | 51.00K | 51.00K | 31.00K | 48.00K | 49.00K | 40.00K |
| EBITDA | -19.00M | -21.25M | -15.72M | -12.23M | -11.81M | -9.83M | -8.14M | -6.90M | -5.04M | -3.67M | -2.15M | -703.63K | -1.33M | -239.00K | 112.00K | -3.32M | 1.19M | -9.24M | -2.62M | -2.90M | 2.37M | -297.00K | -926.00K | -1.18M |
| EBITDA Ratio | -869.12% | -2,039.67% | -1,551.73% | -1,605.51% | -1,354.73% | -1,449.12% | -1,296.66% | -1,390.16% | -1,402.77% | 0.00% | -315.61% | -72.61% | -96.09% | -13.76% | -20.46% | -65.32% | -178.54% | -197.16% | -122.01% | -122.01% | 1.74% | -31.11% | -68.37% | -100.26% |
| Operating Income | -21.76M | -24.21M | -17.24M | -13.73M | -13.14M | -10.90M | -8.93M | -7.44M | -5.45M | -3.88M | -1.35M | -1.07M | -2.75M | -254.00K | 74.00K | -3.38M | 1.09M | -9.51M | -2.80M | -2.80M | 2.28M | -356.00K | -1.12M | -1.22M |
| Operating Income Ratio | -995.38% | -2,325.36% | -1,701.38% | -1,801.97% | -1,508.09% | -1,607.52% | -1,422.45% | -1,492.97% | -1,509.42% | 0.00% | -168.54% | -110.64% | -195.45% | -10.50% | 3.02% | -66.73% | 28.12% | -281.49% | -68.41% | -68.41% | 79.35% | -17.95% | -62.82% | -104.35% |
| Total Other Income/Expenses | 127.00K | -232.00K | -128.00K | -14.00K | -414.00K | 28.00K | 8.00K | 25.00K | 22.00K | 9.00K | 13.00K | 41.00K | 40.55K | -7.00K | -8.00K | 14.00K | 32.00K | 197.00K | 132.00K | 242.00K | 46.00K | 6.00K | 143.00K | -103.00K |
| Income Before Tax | -21.63M | -24.44M | -17.36M | -13.75M | -13.56M | -10.87M | -8.93M | -7.41M | -5.43M | -3.87M | -1.24M | -1.03M | -2.71M | -261.00K | 66.00K | -3.37M | 1.12M | -9.31M | -2.67M | -2.67M | 2.33M | -350.00K | -979.00K | -1.33M |
| Income Before Tax Ratio | -989.57% | -2,347.65% | -1,714.02% | -1,803.81% | -1,555.59% | -1,603.39% | -1,421.18% | -1,487.95% | -1,503.32% | 0.00% | -154.56% | -106.35% | -192.54% | -10.79% | 2.69% | -66.45% | 28.94% | -275.66% | -65.18% | -65.18% | 80.95% | -17.65% | -54.82% | -113.14% |
| Income Tax Expense | -1.50M | -2.75M | -2.35M | -2.14M | -2.22M | -1.94M | -1.39M | -1.02M | -309.00K | -275.00K | -1.51M | -123.32K | 1.24M | -80.00K | -137.00K | 230.00K | -89.00K | -201.00K | -142.00K | -142.00K | 37.00K | 2.00K | -28.00K | 8.00K |
| Net Income | -20.13M | -21.69M | -15.01M | -11.61M | -11.33M | -8.94M | -7.56M | -6.57M | -4.89M | -3.59M | -1.06M | -865.74K | -2.59M | -354.00K | -44.00K | -3.60M | 1.21M | -9.11M | -2.53M | -2.53M | 2.29M | -352.00K | -951.00K | -1.33M |
| Net Income Ratio | -920.95% | -2,083.19% | -1,481.93% | -1,523.10% | -1,300.52% | -1,318.88% | -1,203.18% | -1,318.67% | -1,355.40% | 0.00% | -132.83% | -89.34% | -183.72% | -14.63% | -1.79% | -70.99% | 31.24% | -269.71% | -61.72% | -61.72% | 79.66% | -17.75% | -53.25% | -113.14% |
| EPS | -0.08 | -0.09 | -0.07 | -0.07 | -0.07 | -0.07 | -0.08 | -0.09 | -0.08 | -0.08 | -0.02 | -0.02 | -0.08 | -0.01 | 0.00 | -0.13 | 0.05 | -0.34 | -0.14 | -0.14 | 0.20 | -0.04 | -0.09 | -0.13 |
| EPS Diluted | -0.08 | -0.09 | -0.07 | -0.07 | -0.07 | -0.07 | -0.08 | -0.09 | -0.08 | -0.08 | -0.02 | -0.02 | -0.08 | -0.01 | 0.00 | -0.13 | 0.05 | -0.34 | -0.14 | -0.14 | 0.19 | -0.04 | -0.09 | -0.13 |
| Weighted Avg Shares Out | 260.44M | 246.58M | 225.07M | 178.04M | 163.95M | 136.40M | 95.50M | 73.35M | 58.86M | 47.63M | 45.13M | 40.58M | 34.40M | 28.73M | 26.83M | 26.80M | 26.75M | 26.77M | 17.59M | 17.58M | 11.21M | 10.06M | 10.06M | 10.06M |
| Weighted Avg Shares Out (Dil) | 260.47M | 246.58M | 225.07M | 178.04M | 163.95M | 136.40M | 95.50M | 73.35M | 58.86M | 47.63M | 45.13M | 40.58M | 34.40M | 28.73M | 26.83M | 26.80M | 26.75M | 26.77M | 17.59M | 17.58M | 11.78M | 10.06M | 10.06M | 10.06M |
ANGLE primed for commercialisation, says leading American investment bank
Jefferies reckons ANGLE PLC (AIM:AGL, OTCQX:ANPCY) is primed for commercialisation and has a cash runway that takes it well into 2024. In a note, the bank, which is well regarded in the healthcare space, said shares in the diagnostics specialist...
ANGLE falls on £20mln discounted placing
ANGLE PLC (AIM:AGL, OTCQX:ANPCY) fell 13% to 81.8p after it raised £20mln through a placing at 80p with the med-tech firm's directors chipping in £130,000 through a management subscription. The price was a 14.4% discount on the closing market price...
ANGLE hails Innsbruck prostate cancer treatment data
ANGLE PLC said an Austrian study has shown its Parsortix liquid biopsy system potentially could be used to monitor drug response in cancer trials, helping assess patients before, during and after therapy. The assertion followed the release of the latest...
ANGLE pleased with results of independent study of its Parsortix system
ANGLE PLC (AIM:AGL), the liquid biopsy specialist, said its Parsortix system has performed favourably in an independent study of metastatic breast cancer (MBC) patients. The preliminary study by the Institute of Oncology, Ljubljana, Slovenia compared ANGLE's Parsortix system to an...
ANGLE looks to change the game for cancer detection
What ANGLE does ANGLE plc (LON:AGL, OTCQX:ANPCY) is the firm behind Parsortix – a simple blood test which can help doctors spot the signs of cancer at an early stage. Blood tests – or liquid biopsies as they are known...
Source: https://incomestatements.info
Category: Stock Reports